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Unrepaired DNA Breaks in p53-Deficient Cells
Lead to Oncogenic Gene Amplification
Subsequent to Translocations
ular mechanisms that generate complicons are poorly
understood, due partly to their inherent complexity and
diversity, as well as lack of experimental models to track
progression from initiation to final outcome.
The classic nonhomologous end-joining (NHEJ) path-
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strand breaks (DSB) between participating gene seg-Brigham and Women’s Hospital
ments and flanking recombination signal sequencesBoston, Massachusetts 02115
(RSSs) (Fugmann et al., 2000). Subsequently, V(D)J re-
combination is completed via repair of resultant DSBs
by NHEJ. Deficiency for any NHEJ factor results in aSummary
substantial defect in V(D)J coding joint formation, and
thus a severe combined immunodeficiency (SCID) (re-Amplification of large genomic regions associated
viewed in Bassing et al., 2002).with complex translocations (complicons) is a basis
Mice deficient for XRCC4, Lig4, or Ku also suffer exten-for tumor progression and drug resistance. We show
sive apoptosis of developing neurons, with XRCC4/ andthat pro-B lymphomas in mice deficient for both p53
DNA Lig4/ mice exhibiting late embryonic lethalityand nonhomologous end-joining (NHEJ) contain com-
(Frank et al., 1998; Gao et al., 1998; Gu et al., 1997). Inplicons that coamplify c-myc (chromosome 15) and IgH
these mice, neuronal apoptosis and embryonic lethality(chromosome 12) sequences. While all carry a translo-
are dramatically rescued by homozygous inactivationcated (12;15) chromosome, coamplified sequences are
of the p53 tumor suppressor gene (Frank et al., 2000;located within a separate complicon that often involves
Gao et al., 2000). However, lymphocyte development isa third chromosome. Complicon formation is initiated by
not rescued, because p53 and NHEJ-deficient prolym-recombination of RAG1/2-catalyzed IgH locus double-
phocytes still cannot properly join V(D)J segments. De-strand breaks with sequences downstream of c-myc,
spite survival to adulthood, rescued XRCC4/,p53/generating a dicentric (15;12) chromosome as an amplifi-
or Lig4/,p53/ (hereafter referred to as X/P and L/P,cation intermediate. This recombination event employs
respectively) mice, as well as those doubly deficienta microhomology-based end-joining repair pathway, as
for Ku80 (or DNA-PKcs) and p53, routinely succumb toopposed to classic NHEJ or homologous recombination.
pro-B cell lymphomas between 6 and 16 weeks afterThese findings suggest a general model for oncogenic
birth (Difilippantonio et al., 2000; Frank et al., 2000; Gaocomplicon formation.
et al., 2000; Lim et al., 2000; Vanasse et al., 1999). The X/P
and L/P lymphomas universally harbor an unbalanced,
Introduction
nonreciprocal translocation containing a distal portion
of chromosome 15 fused to the majority of chromosome
A hallmark of tumorigenesis is genomic instability, which 12, der(12)t(12;15), which we hereafter refer to as C12;15
manifests as chromosomal aberrations such as translo- (with C identifying the derivative chromosome containing
cations and amplifications (reviewed in Lengauer et al., the centromere). Moreover, the X/P and L/P lymphomas,
1998). While these changes can be simple, such as bal- as well as the Ku80/,p53/ lymphomas, contain sub-
anced reciprocal translocations or localized gene ampli- stantial amplification of both c-myc and segments of
fication, many involve complex unbalanced transloca- the IgH locus. The chromosomal alterations in these
tions associated with amplification of sizable regions. tumors were noted to be reminiscent of those in human
The latter events, which we refer to collectively as com- Burkitt’s lymphomas (Difilippantonio et al., 2000). How-
plicons, have been noted in association with pathogene- ever, the relationship between the recurrent chromo-
sis and progression of various solid and disseminated some 12 and 15 translocations and c-myc/IgH amplifica-
cancers (Coene et al., 1997; Padilla-Nash et al., 2001). tion is unknown.
Complicons can also be associated with the acquisition Gene amplification generally refers to an increased
of resistance to chemotherapeutic agents in vitro (Fed- dosage of a gene or genomic region. Mammalian gene
erspiel et al., 1984) and in vivo (Gorre et al., 2001). Molec- amplification was discovered as the mechanism under-
lying overproduction of dihydrofolate reductase in meth-
otrexate-resistant mammalian cells (Alt et al., 1978).6 Correspondence: alt@rascal.med.harvard.edu
7 These authors contributed equally to this work. Subsequent studies revealed amplification both as a
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Figure 1. X/P and L/P Mice Exhibit Amplified IgH and c-myc Loci with Overexpression of the c-myc Gene
(A) Southern blot analysis of tumor samples and controls (tail DNA from normal mice). Fold amplification of c-myc is indicated below each
lane and is shown relative to control lanes and normalized for loading (control probe, fragment of the LR8 gene detecting a 14 kb genomic
fragment). Asterisk: DNA from tumor #42 was partially degraded, the fold of amplification is possibly underestimated. Amplification at the IgH
and c-myc regions is confirmed by array CGH data (see Supplemental Data at http://www.cell.com/cgi/content/full/109/7/811/DC1).
(B) A typical array-CGH profile from tumor #155. Blue trace indicates the ratio of the test to reference hybridization signal. Red indicates the
ratio of the reference to test. Symmetric blue over red peaks indicate amplified regions.
(C) Northern blot of tissue from normal mice and tumor samples is shown with loading control (GAPDH probe). Expression level of c-myc is
indicated relative to the expression level in normal thymus normalized for loading (control probe, GAPDH).
(D) Survival curves for XRCC4/ p53/, XRCC4/ p53/, and RAG2/ XRCC4/ p53/ mice. Percent survival is indicated as a function
of age. (X4/ p53 / [n  8]; X4/ p53 / [n  12]; R2/ X4/ p53/ [n  6]).
common mechanism for anticancer drug resistance, and of drug resistance (Livingstone et al., 1992; Yin et al.,
1992). In this regard, p53 deficiency was suggested toalso as a characteristic of an ever-increasing number
of human tumors (reviewed in Kuehl and Bergsagel, allow cells to move inappropriately into S phase and
acquire DSBs that initiate amplification (Paulson et al.,2002; Schwab, 1999). In the latter context, amplification
commonly results in overexpression of cellular onco- 1998). On the other hand, it also is conceivable that
checkpoint deficiencies allow replication of preexistinggenes and has been implicated in several stages of
tumor development (Lengauer et al., 1998). Studies of DSBs, thus creating chromatid substrates for BFB am-
plification.acquired drug resistance in transformed cell lines have
led to the articulation of several different models for In contrast to standard amplification in drug-resistant
cells, little is known about the mechanism of complicongene amplification. Broadly, these models include un-
equal sister chromatid exchange, extrachromosomal formation in the context of cytogenetic tumor progression.
Herein, we report that X/P and L/P mice reproduciblyamplification and reintegration, localized overreplica-
tion, and breakage-fusion-bridge cycles (reviewed in succumb to pro-B cell lymphomas that feature compli-
cons harboring coamplified c-myc and IgH sequences.Stark, 1993).
Cytogenetic evidence suggested that DNA breakage In addition, we elucidate, in detail, the molecular mecha-
nism by which these complicons arise.could play a key role in amplification (Windle et al., 1991).
In this regard, drug resistance studies showed that am-
plification rates can be increased by ionizing radiation Results
(Paulson et al., 1998) or clastogenic compounds (Kuo
et al., 1994; Livingstone et al., 1992; Paulson et al., 1998), Amplification and Overexpression of c-myc
in L/P or X/P Pro-B Cell Lymphomasas well as by proximity to chromosome fragile sites
(Coquelle et al., 1997) or DSBs (Pipiras et al., 1998). X/P mice and L/P mice reproducibly develop pro-B cell
lymphomas that contain a C12;15 translocation andVarious studies also suggested that DNA breakage
could initiate a classic breakage fusion bridge (BFB) show genomic coamplification of the cellular protoonco-
gene c-myc and IgH sequences. We exploited this sys-mechanism (McClintock, 1941), in which broken sister
chromatids would fuse at their termini to generate dicen- tem to study molecular mechanisms of gene amplifica-
tion leading to tumorigenesis. We have analyzed a totaltrics that could reenter the BFB cycle (Ma et al., 1993;
Smith et al., 1990; Toledo et al., 1992). Other studies of 20 L/P or X/P mice. All doubly deficient animals were
smaller than wild-type littermates and developed tumorsshowed that p53 suppresses amplification in the context
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between 6 and 12 weeks after birth. All tumors were analyses revealed that c-myc transcript levels in four
B220-positive and negative for surface IgM expression different tumors analyzed were substantially greater
(data not shown and Frank et al., 2000; Gao et al., 2000), than levels in a normal adult thymus (Figure 1C), the
confirming pro-B lymphocyte origin. normal tissue that exhibits highest c-myc expression
To assay for c-myc amplification, tumor DNA was (Zimmerman and Alt, 1990).
analyzed by Southern blotting for hybridization with a
promoter-proximal c-myc probe. All but two of 20 ana- Requirement for RAG in Pro-B Lymphomagenesis
lyzed X/P or L/P pro-B lymphomas showed substantial in X/P Mice
amplification (Figure 1A; see Supplemental Data at The C12;15 and associated IgH and c-myc amplification
http://www.cell.com/cgi/content/full/109/7/811/DC1; in X/P and L/P pro-B cell tumors suggested that the
Frank et al., 2000; Gao et al., 2000). Significantly, the translocation/amplification process may involve RAG-
two tumors with no (#184) or, at most, modest (#146) initiated DSBs (Frank et al., 2000; Gao et al., 2000). We
c-myc amplification appeared distinguishable from the tested this directly by examining triple mutant mice defi-
others based on the nature of their translocations (see cient for RAG2, p53, and XRCC4, which were obtained
below). All pro-B cell tumors also contained discrete as offspring from parents that were XRCC4/, p53/
IgH locus rearrangements. Of these, most contained an (or p53/), and RAG/ (or RAG/). Six XRCC4/,
amplified JH allele (see Supplemental Data; Frank et al., p53/, RAG/ mice were obtained, and all were ap-
2000; Gao et al., 2000), suggesting that amplified trans- proximately 50% the size of XRCC4/ or XRCC4/
location breakpoints may occur within the JH region. As littermates, as previously reported for p53-rescued Lig4-
JH rearrangements in X/P or L/P progenitor B cells can or XRCC4-deficient mice (Frank et al., 2000; Gao et al.,
lead to deletion of the JH locus (Frank et al., 2000; Gao 2000). Two triple mutant mice died early from unknown
et al., 2000), we also assayed tumor DNAs for hybridiza- causes other than pro-B lymphoma, and four others
tion to downstream IgH probes. Significantly, all 18 lym- were sacrificed when moribund between 78 and 97 days
phomas that clearly contained c-myc amplification also of age (Figure 1D). Median survival time for these mice
had IgH locus amplification, as demonstrated by an appeared longer than that of X/P mice (p  0.1). More
HS3a enhancer probe (see Supplemental Data). The lat- importantly, necropsy of four mice and complete histo-
ter element derives from the 3 IgH regulatory region logic analysis of one revealed no anatomic or micro-
(IgH3RR) 200 kb downstream from the JH locus (Manis scopic evidence of lymphoma, in striking contrast to
et al., 2002). X/P mice which nearly all developed lymphomas (p 
To examine the specificity of the IgH and c-myc ampli- 0.01). In fact, no abnormal masses were identified, ren-
fication, we surveyed the entire genome of selected dering an exact cause of death difficult to determine,
tumors for additional amplifications and deletions via although histology revealed a wide variety of degenera-
array-based comparative genomic hybridization (array- tive anomalies in multiple organ systems, as well as
CGH) (Pinkel et al., 1998; Sharpless et al., 2001). Array- two microscopic medulloblastomas (D.O.F., Y.G., and
CGH detects amplification and deletion by simultaneous F.W.A., unpublished data). However, given the complex-
comparative hybridization to a genomic BAC array with ities in generating triple mutant mice, the significance
normal control DNA and experimental sample DNA. Four of the latter findings await analyses of p53-deficient,
tumors (#155, #42, #171, and #306), with evidence of conditional NHEJ-deficient mice. Overall, our results
significant IgH/c-myc amplification based on Southern clearly demonstrate that occurrence of X/P pro-B lym-
blotting, were analyzed by array-CGH. Of these, three phomas requires integrity of the RAG2 gene.
of four showed substantial amplification of a distal re-
gion on chromosome 12, in the vicinity of the JH locus Complex Translocations Associated(Figure 1B; see Supplemental Data at http://www.cell.
with Amplificationcom/cgi/content/full/109/7/811/DC1). IgH locus amplifi-
Because X/P and L/P mice exhibit significant genomiccation as judged by Southern blotting in the single tumor
instability, even in some nontransformed cells (reviewed(#306) that did not show chromosome 12 amplification
in Ferguson and Alt, 2001), genomic rearrangementsby array-CGH suggests that the amplified segment of
other than C12;15 may occur in X/P or L/P lymphomas.chromosome 12 in this tumor was below the 3 megabase
To assay for additional chromosomal aberrations, wepair resolution of the array-CGH assay. Additionally, all
performed spectral karyotyping (SKY) (Liyanage et al.,four assayed tumors showed amplification of a medial
1996) on metaphases from 8 L/P tumor-derived cell cul-region of chromosome 15, in the vicinity of the c-myc
tures. SKY confirmed the presence of a C12;15 translo-gene (Figure 1B; see Supplemental Data). The only other
cation in all (e.g., Figures 2A and 2C; representativedefinitive amplification detected by array-CGH occurred
data), with nearly 100% of the metaphases exhibitingin tumor #155 and involved a portion of chromosome
this translocation in most tumors. In addition to the14 spanning the TCR locus, a result confirmed by
C12;15, SKY also revealed the presence of complexSouthern blotting (data not shown). In addition to c-myc
translocations harboring portions of chromosomes 12and IgH locus amplification, the array CGH analyses
and 15. Most often, these structures involved chromo-suggested a possible recurrent deletion within chromo-
some 12- and 15-derived material fused to material fromsome 9 (see Supplemental Data).
a third chromosome. For example, a tripartite transloca-Deregulation of c-myc expression often appears to
tion, der(15)t(12;15)t(6;12), containing the centromere ofplay a crucial role in malignant transformation of human
chromosome 15 attached to chromosome 12 materialB lineage cells. Thus, we assayed for c-myc transcripts
and terminating with chromosome 6 material (denotedin X/P and L/P tumors via Northern blotting with a probe
specific for the first and second c-myc exons. These as C15;12;6), was observed in tumor #162 (Figure 2A).
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Figure 2. X/P and L/P Lymphomas Harbor Complicons Containing Coamplified c-myc and IgH
(A and C) Spectral karyotype (SKY) analysis of tumors #162 (A) and #554 (C).
(B and D). Fluorescence in situ hybridization (FISH) with locus-specific probes and chromosome paints of tumors #162 (B) and #554 (D).
Chromosome 12 is red, chromosome 15 is green. Locus-specific signals are white (yellow arrows); IgH, left; c-myc, right. All chromosomes
are counterstained with DAPI (blue).
Other examples include a C15;12;3 in tumor 554 (Figure recurrent C12;15 translocations, we performed FISH
analyses with a telomere-15-proximal probe; these anal-2C) and a C15;12;14 in tumor R3 (see Supplemental Data
at http://www.cell.com/cgi/content/full/109/7/811/DC1). yses indicated that the C12;15, while lacking c-myc (ex-
cept in a subset of tumor #127 metaphases), harboredIn another tumor (#127), chromosome 12- and 15-derived
material were located on a chromosome 6 derivative, the telomere-proximal region of chromosome 15, indi-
cating that it generally derived from chromosome 15generating a C6;15;12;6, while in yet another tumor
(#155), there was a C12;15 as well as C12;14 and C14;12 regions downstream of the c-myc gene (see below and
data not shown). In summary, c-myc and IgH weretranslocations likely related to the amplification of chro-
mosome 14 TCR locus sequences (see Supplemental coamplified and associated with a complex transloca-
tion product that usually was either (1) derived fromData).
Previous FISH data demonstrated coamplification of chromosome 15 and terminated with material from a
third, nonhomologous chromosome, or (2) derived fromIgH and c-myc in NHEJ/p53 double null pro-B lymphoma
cells (Difilippantonio et al., 2000; Gao et al., 2000). While a third chromosome but contained coamplified IgH/
c-myc embedded within the translocation product. Init seemed likely that the amplified sequences might be
on the recurrent C12;15, these studies did not reveal addition, IgH and c-myc loci were generally absent from
the clear-cut C12;15.the amplicon location. For this purpose, FISH analyses
were performed using probes specific to the c-myc and
IgH loci, in conjunction with whole-chromosome paints Microhomology at the Translocation Junctions
The recombination pathway that leads to chromosomalspecific for chromosomes 12 and 15. Surprisingly, these
studies revealed that the amplified c-myc and IgH se- translocations in the absence of NHEJ is unknown. One
possibility is homologous recombination (HR). Alterna-quences were associated with complex translocations
and not with the C12;15 (Figures 2B and 2D and data tively, RAG may promote transchromosomal recombi-
nation. A potential molecular footprint of such pathwaysnot shown). For example, in tumors #162 and #554,
coamplified IgH/c-myc sequences were located on the would be DNA homology tracts or cryptic RSSs at or
near translocation junctions. Breakpoint sequencescomplex derivative chromosome 15 (Figures 2B and 2D),
and in tumor #127 the coamplified IgH/c-myc was on from nine separate translocation junctions were ana-
lyzed and mapped to the single nucleotide level. In allthe chromosome 6 derivative (data not shown).
None of the tumors analyzed routinely contained even cases, translocation junctions contained very short (1–6
nucleotides) sequence homologies (Figure 3A), sug-single-copy IgH or c-myc sequences on the C12;15 (e.g.,
Figures 2B and 2D), although a subset of tumor #127 gesting involvement of an end-joining pathway, still not
well characterized, that employs such short homologiesmetaphases contained apparently low or single-copy
IgH and c-myc on a C12;15 and a C15;12 (data not (Roth and Wilson, 1986). There was no apparent nucleotide
addition at any of these junctions. Germline sequencesshown). As neither the C15;12- nor the C12;15-con-
taining c-myc were observed in any other tumors, we surrounding chromosome 12 and 15 breakpoints con-
tained no significant sequence homologies. Likewise,speculate these translocations may represent compli-
con-related by-products and/or independent transloca- no obvious RSSs were found in the sequences closely
flanking the chromosome 15 breakpoints.tion events in tumor #127. To further characterize the
Mechanism of Complicon Formation
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Figure 3. Translocation Junctions Contain
Microhomologies and Result in Dicentric
Chromosomes
(A) Sequences of cloned translocation junc-
tions are aligned to their corresponding deriv-
ative germline sequences. Chromosome 12
sequence is aligned above the junction se-
quence and chromosome 15 sequence is
aligned below. Microhomologies at the junc-
tions are boxed and shown in bold. The con-
figuration of the translocation product is indi-
cated on the right. Junctions that occur
downstream of c-myc are shown in the first
group, junctions that occur upstream of
c-myc are shown in the second group, and
the chromosome 12-12 junction containing
divergently fused JH sequences (tumor #171)
is indicated at the bottom.
(B) Map of translocation breakpoints. Each
breakpoint is assigned a number correspond-
ing to the alleles described in Table 1. Ampli-
fied breakpoints are shown in red. Map is not
drawn to scale.
Dicentric Configuration of Amplified an approximately 2 kb region 372–374 kb downstream
of c-myc (Figure 3B; see Discussion).Translocation Products
To determine the precise locations of the breaks for In addition to the six downstream junctions, two junc-
tions were mapped to 134 kb (in tumor #146) and 2700each translocation, breakpoint sequences were mapped
by comparison to genomic sequence databases (Gen- kb (in tumor #171) upstream of c-myc (Figure 3B, Table
1). The upstream junction in 146 was not amplified, andBank; Celera CDS). All chromosome 12 breakpoints
were clustered in a 2.5 kilobase pair region spanning this tumor also lacked an obvious complicon or substan-
tial c-myc amplification (see Supplemental Data). ThisJH1 to JH4, consistent with these breakpoints resulting
from a RAG-initiated DSB at a JH segment. In contrast, tumor and tumor #184, which has an alteration in the 5
portion of c-myc in the absence of amplification (seebreakpoints on chromosome 15 were widely distributed.
Six junctions were mapped to positions ranging from above; Gao et al., 2000), may have activated the c-myc
gene by a different mechanism than the others (see70 kb to more than 700 kb downstream of c-myc (Figure
3B, Table 1). Southern blotting demonstrated that each Discussion). Tumor #171 also contained an amplified JH
to JH junction (Figures 3A and 3B) that likely was gener-of these downstream junctions was amplified (Figure 1
and see Supplemental Data at http://www.cell.com/cgi/ ated by mechanisms related to complicon formation
(see Discussion). Although tumor #171 contained highlycontent/full/109/7/811/DC1). While the junctions were
spread over an approximately 600 kb region, several amplified c-myc sequences, as well as the amplified JH
to JH junction (Table 1), its junction 5 of c-myc did notclusters were observed, including three junctions within
Cell
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Table 1. Junction Breakpoints and Amplification
Tumor # Breakpoint 12 Breakpoint 15 Amplification
554 JH region1 705 kb downstream myc1 12-fold
294 JH region2 70 kb downstream myc2 11-fold
213 JH region3 372 kb downstream myc3 20-fold
248 JH region4 373 kb downstream myc4 7-fold
162 JH region5 374 kb downstream myc5 10-fold
42a JH region6 280 kb downstream myc6 4-foldb
127 JH regionc 90 kb downstream myc7 9-fold
146a JH region8 134 kb upstream myc8 NA
171 a JH region9 2711 kb upstream myc9 NAd
171 b JH/JH10/10 — 11-fold
a Tumors listed here are either XRCC4 or Lig4, p53 double-deficient,
except tumors 42 and 146, which are Lig4, p53, and RAD54 triple-
deficient (Essers et al., 1997). These mice developed pro-B lym-
phoma within 12 weeks of age, indistinguishable from the X/P or
L/P mice. A number is assigned to each junction (superscript above),
and the map of each numbered junction is shown in Figure 3B. NA,
not significantly amplified.
b The c-myc amplification level was complicated by some DNA deg-
radation in this sample and could be greater than 4-fold.
c A 20 kb fragment containing JH sequences was cloned from tumor
127. Limited sequence information indicated that this fragment con-
tains downstream c-myc sequences, but the actual junction has not
been determined.
d Tumor 171 has two junctions, (a) an unamplified rearrangement
containing a JH fused upstream of c-myc, and (b) an amplified EcoRI
fragment that contains only a JH to JH junction.
appear significantly amplified (data not shown). Notably,
chromosome 15-derived sequences adjacent to the 5
of c-myc junction in 171 were amplified in their germline Figure 4. Gene Amplification Process in Action: Fusion of Chroma-
tid Ends and Dicentric Chromosomesconfiguration in tumor 171, as well as in several other
(A) SKY and FISH analyses of a dicentric chromosome in tumortumors that contained amplified downstream junctions
R3. For SKY classification, chromosome 12 and 15 material are(data not shown). This finding is consistent with the
indicated. For FISH: the IgH, red; c-myc, green; overlap, yellow.presence of a large amplicon beginning downstream of
DNA is counterstained with DAPI (blue).c-myc and extending at least 3 Mb upstream of c-myc. (B) FISH analysis of metaphase chromosomes from tumor R3 show-
These findings also indicate that the unamplified junc- ing sister chromatid fusions (panels I and II) versus unfused chroma-
tion 5 of c-myc in tumor #171 likely resulted from an tids (panels III and IV). For each set, DAPI-stained chromosomes
are at left, FISH signals are displayed at right. Fused chromatids areindependent translocation event from that which led to
indicated by yellow arrows and unfused chromatids by red arrows.amplified c-myc.
(C) FISH analysis of metaphase chromosomes from tumor R3. Chro-The orientation of the translocation junction se-
mosome 15-specific paint is displayed in green, and a FISH probequences with respect to the centromeres of the deriva- recognizing the near-telomeric region of chromosome 15 is dis-
tive chromosomes demonstrates that all junctions played in red. Panel I: chromosome 15 with fused chromatids show-
downstream of c-myc occurred in a centromere-to-cen- ing no detectable telomere FISH signal. Panel II: C12;15 transloca-
tion with chromosome 15 material and the near-telomeric FISHtromere (CEN12-CEN15) configuration, such that the ini-
signal. Panel III: Normal chromosome 15.tial translocation product would have resulted in a di-
centric chromosome, C12;15C. By contrast, the two
unamplified translocation junctions (in tumors #146 and
#171) upstream of c- myc occurred in a centromere-to- Further analyses of these tumors by SKY allowed us to
directly visualize rare dicentric translocation productstelomere (CEN12-TEL15) configuration, with the centro-
mere of chromosome 12 acquiring chromosome 15 se- from one tumor (R3). SKY indicated that this dicentric
chromosome was symmetric, containing chromosomequence distal to the breakpoint (Figures 3A and 3B), and
would have generated C12;15 translocations. 12 material between large regions derived from chromo-
some 15 including centromeres (Figure 4A). FISH showed
the coamplification of IgH and c-myc on these dicentricIdentification of Dicentric Chromosomes as
Intermediates in the Amplification Process chromosomes (Figure 4A). Strikingly, some metaphase
chromosomes from this tumor contained a single chro-To generate additional tumors to assay for early events
in the amplification process, we transferred newborn mosome possessing sister chromatids fused at their
ends. FISH again revealed coamplification of IgH andlivers of L/P mice to RAG-deficient recipients. In one
transfer, three tumors with amplified c-myc genes were c-myc coincident with sister chromatid fusion (Figure
4B, images I and II) and a lack of chromosome 15 se-generated, two clonally related by JH rearrangements
and one that was distinct (see Supplemental Data at quences near the telomere, which were present in the
C12:15 and normal chromosome 15 in these meta-http://www.cell.com/cgi/content/full/109/7/811/DC1).
Mechanism of Complicon Formation
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Figure 5. Model for Gene Amplification and
Complex Chromosome Translocations in the
NHEJ/53-Deficient Lymphomas
Double lines represent chromatids. Chromo-
some 12 is depicted in red and chromosome
15 in green. At the ends of the chromatids,
circles represent centromeres and rectangles
represent telomeres. Black symbols situated
between chromatids depict sister chromatid
cohesion complexes. The blue bars shown
for product G indicate material from a third,
nonhomologous chromosome. See Discus-
sion for details.
phases (Figure 4C). Finally, we also observed similar c-myc loci, of human Burkitt’s lymphomas, we now show
that it is clearly different. Moreover, the detailed featureschromosomes with amplified IgH and c-myc sequences
at unfused tips (Figure 4B, images III and IV), consistent of X/P or L/P pro-B lymphomas indicate that they are
likely more revealing of processes (see below) involvedwith broken dicentrics. These unique chromosomal
structures are likely BFB amplification intermediates in generation and progression of human solid tumors
(Schwab, 1999).that are unstable and ultimately give rise to the compli-
cons of more mature tumors.
Unrepaired RAG-Initiated DNA Breaks in X/P
or L/P Pro-B Cells Lead to C12;15Discussion
and C15;12C Translocations
The p53-dependent cell cycle checkpoint responds toMany types of human tumors contain complex translo-
cations with associated amplifications (complicons). DNA damage by inducing cell cycle arrest and/or acti-
vating apoptotic programs (Lane, 1992). In XRCC4- orCell culture studies showed specific DSBs can lead to
translocations (Richardson and Jasin, 2000b) or intra- Lig4-deficient mice, the prolymphocyte pool is small,
as most likely die from a p53-dependent response tochromosomal drug resistance gene amplification (Pipiras
et al., 1998). Likewise, such studies implicated p53 in unrepaired RAG-initiated JH DSBs (Frank et al., 2000;
Gao et al., 2000). In X/P or L/P mice, the pro-B compart-suppression of drug resistance gene amplification (Liv-
ingstone et al., 1992; Yin et al., 1992). In this report, we ment size is restored but development is still blocked
as RAG-liberated V, (D), and J ends cannot be properlyhave now linked all of these processes in the setting of
tumorigenesis. Thus, in p53-deficient pro-B cells, RAG- joined without NHEJ (Frank et al., 2000; Gao et al., 2000).
This substantial X/P or L/P pro-B cell population withinitiated DSBs that cannot be repaired by NHEJ inevita-
bly lead to evolution of amplified c-myc complicons and, unrepaired Rag-induced DSBs provides a reservoir of
cells poised for initiating translocations that lead toultimately, to pro-B cell lymphomas.
We have elucidated several features of X/P or L/P transformation. In this context, pro-B cells have been
shown to actively cycle in the absence of productivelymphomas, which form the basis for a model of onco-
genic complicon formation (Figure 5). These include: IgH rearrangements (Kline et al., 2001). While the pro-T
cell population should similarly be at risk in X/P or L/Prequirement for a functional RAG2 gene for their genera-
tion; presence of a C12;15 nonreciprocal translocation mice, absence of X/P or L/P pro-T lymphomas suggests
that initiating events are more rare in pro-T cells and/product, which lacks c-myc or JH-proximal IgH se-
quences; coamplification of IgH and c-myc sequences or that potential selective advantages conferred are
weaker. A study of CAD gene amplification in a p53-within a complicon and not within the C12;15; occur-
rence of amplified chromosome 12 to chromosome 15 expressing line with a defective G1 checkpoint sug-
gested that checkpoint defects may allow cells to inap-junctions downstream of c-myc in a dicentric orienta-
tion; presence of chromosomal intermediates relevant propriately move into S phase and subsequently acquire
DSBs that initiate amplification (Paulson et al., 1998).to amplification, including a dicentric C15;12C with am-
plified c-myc and IgH sequences; and generation of RAG-induced DSBs that initiate complicon formation in
X/P or L/P pro-B cells occur in G1 or G0 (Lee and Desi-translocation junctions by an end-joining pathway that
uses short homologies. Although the universal C12;15 derio, 1999). In this context, our findings of chromosome
12 sequences in two different translocations within eachin X/P and L/P lymphomas appeared potentially analo-
gous to the classic t(8;14), which harbors fused IgH and tumor and of amplified JH sequences fused in inverted
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orientation in one may be relevant. Together, they imply 1997; Li et al., 1995; Taccioli et al., 1993). Finally, in vitro
studies have also implicated an alternative end-joiningthat X/P- or L/P-deficient pro-B cells with RAG-initiated
JH DSBs cycle into S phase where the DSBs are repli- pathway (Baumann and West, 1998).
cated and ultimately initiate downstream transformation
events (Figure 5, steps 1 and 2). Complicons Are Generated by BFB Cycles
from a C15;12C Dicentric
Most human lymphoid malignancies and murine plas-Initiation of Complicon Formation: Linked C12;15
and C15;12C Events macytomas have IgH and c-myc translocations with
breakpoints upstream or within c-myc, likely activatingA remarkable feature of X/P or L/P pro-B lymphomas is
that they usually harbor both a C12;15 as well as a it via activities of IgH enhancers without amplification
(Kuehl and Bergsagel, 2002). Although infrequent com-complicon resulting from a C15;12C dicentric. We have
not identified the C12;15 junction. However, it is distinct pared to amplification, we observed similar events in
two lymphomas (#146 and #184; Gao et al., 2000; seefrom amplified junctions, as it usually lacks chromosome
12 sequences proximal to the JH region (rendering isola- Supplemental Data at http://www.cell.com/cgi/content/
full/109/7/811/DC1). In contrast, all amplified transloca-tion difficult), and involves a more classic C12;15 union
with respect to orientation. The C12;15 and the C15;12C tion breakpoints in X/P or L/P lymphomas occur 70 to
700 kb downstream of c-myc on chromosome 15. Infre-might result from separate events, with the C12;15 also
selected based on an unknown growth advantage. How- quent translocation junctions in human tumors involving
IgL loci occur downstream of c-myc but do not resultever, this coincidence may be better explained by mech-
anistic linkage of C15;12C and C12;15 formation. In the in dicentrics due to the relative orientation of IgL and
c-myc loci. These junctions suggested potential involve-latter scenario, RAG-initiated DSBs in X/P or L/P prolym-
phocytes would be replicated to yield sister chromatids ment of downstream sequences, most notably the plas-
macytoma variable translocation-1 (pvt-1), which residesterminated with IgH locus DSBs held in close proximity
due to sister chromatid cohesion established during repli- about 200 kb downstream (Cory et al., 1985). However,
our junctions are more widespread (occurring over ancation (Figure 5, step 2; reviewed in Carson and Christman,
2001). Because the lagging strand cannot replicate to approximately 600 kb region), with some separating
c-myc from pvt-1. As c-myc overexpression is a univer-a broken end, a significant 3 overhang may result on
one sister chromatid, which could become linked to sal feature of all X/P or L/P lymphomas assayed, the
location of complicon-initiating translocations down-chromosome 15 to yield the observed C12;15 lacking
c-myc and JH sequences (Figure 5, step 3; product A). stream of c-myc is likely selected based on an efficient
mechanism for c-myc overexpression via amplification.The remaining broken chromatid of 12 could then re-
combine to the other portion of chromosome 15 to yield However, we do not exclude additional roles of ectopic
elements such as the 3IgHRR, given the long-rangethe dicentric chromosome (Figure 5, step 4; product B).
Directionality of these recombination events might have activity of this putative LCR (reviewed in Manis et al.,
2002) and our finding that it is coamplified in the compli-a mechanistic basis (Richardson and Jasin, 2000a), but
in any case would be insured by selection for the dicen- cons. Finally, we note significant clustering of individual
amplified junctions on chromosome 15, most notablytric (see below).
The recombination process that generates the C12;15 three junctions within 372 to 374 kb downstream of
c-myc. Thus, these junctions are likely targeted by somecould be homology mediated or occur via another path-
way distinct from NHEJ. One conceivable initiating mechanistic feature, for example potential fragile sites,
localized homologies potentially used to generate themechanism would be occurrence of independent DSBs
on chromosome 15, for example due to fragile sites C12;15 lesion, or a higher order process that promotes
accessibility or proximity (Djalali et al., 1987).(Debatisse et al., 1998). Alternatively, the potential 3
overhang on one replicated IgH locus DSB could provide Classic BFB cycles (McClintock, 1941) following di-
centric formation are a common mechanism for intra-a leading strand for a homology-based recombination
event; this could leave a DSB on the remaining portion chromosomal gene amplification in drug-resistant mam-
malian cells (reviewed in Stark, 1993). In this context,of chromosome 15, as a replication byproduct, that
could be coupled to the remaining JH by end joining. In we observed predicted dicentric C15;12C (Figure 5,
product B) and other intermediates (Figure 5, productsthis context, there is experimental precedent for coupled
HR/end-joining recombination events (Richardson and D–F) harboring amplified IgH and c-myc sequences in
L/P tumor cells. Together, these observations suggestJasin, 2000a). In any case, ligation of the chromosome
12 and chromosome 15 ends to generate dicentrics the sole requirement for oncogenic c-myc amplification
in X/P or L/P cells is a C15;12C with the junction fallingclearly involves an end-joining pathway that employs
short homologies, perhaps facilitated by proximity of downstream of c-myc. In the absence of p53, a single
such initiating event could be amplified rapidly and inevi-complexed chromosome 12 and 15 ends. In the latter
context, microhomology-mediated end joining has re- tably by successive BFB cycles (Figure 5, step 8). Ulti-
mately, amplified, unstable chromosomes can be healedcently been characterized as a genetically distinct DNA
repair pathway (Verkaik et al., 2002) and is observable by recombination with the telomere-containing region
of a separate chromosome (e.g., chromosomes 3 andin NHEJ-deficient yeast cells and murine cell lines (Roth
and Wilson, 1986; Boulton and Jackson, 1996a, 1996b; 6) (Figure 5, step 9, product G). In X/P or L/P lymphomas,
the greatly increased frequency of c-myc amplificationKabotyanski et al., 1998). Furthermore, this microhomol-
ogy-mediated pathway catalyzes aberrant V(D)J coding versus ectopic activation of unamplified c-myc indicate
that overall events leading to amplification are moreand signal joining in NHEJ-deficient cells (Bogue et al.,
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SKY and FISH Analysesfrequent than those leading to ectopic activation. In ad-
Lymphoma cultures were grown overnight in the presence of 25dition, our finding of an inverted amplified JH to JH fusion
ng/ml of IL7 and exposed to 50 ng/ml of colcemid (GIBCO-BRL,suggests a related, alternative route to complicon for-
KaryoMAX Colecemid solution) for 3–12 hr. Preparation of meta-
mation. In this case, sister chromatids harboring repli- phase chromosomes, SKY analyses, flourescence in situ hybridiza-
cated JH DSBs would be fused to each other, via the tion (FISH), and whole-chromosome painting using single-chromo-
some-specific paints were performed as previously describedalternative end-joining pathway, go through a BFB cycle,
(Sharpless et al., 2001). FISH probes were as follows: c-myc, a 20 kband then initiate c-myc complicon formation as above
EcoRI fragment subcloned into pBluescript spanning the genomicbut from a different broken chromosome 12 end gener-
locus; IgH, a plasmid containing the S1 through C1 regions of theated via the first BFB cycle.
IgH locus, as previously described (Skok et al., 2001); JH region of
the IgH locus, a 6 kb EcoRI fragment subcloned into pBluescript
containing JH1–JH4 and E. A BAC from the distal near-telomeric
General Implications of Complicon Formation region of mouse chromosome 15 was obtained from Research Ge-
in X/P and L/P Pro-B Lymphomas netics.
We have demonstrated several general features of com-
Cloning and Sequencing of Translocation Junctionsplicon formation in NHEJ/p53-deficient cells. First, the
Tumor DNA samples were digested to completion with EcoRI, andinitiating dicentric translocation results from a DSB that
fragments were cloned into either lambda ZAP II vector (Stratagene)is repaired via an end-joining pathway, which is indepen-
or lambda DASH II vector (Stratagene). Libraries were screened
dent of classic NHEJ and HR and employs microhomolo- according to standard protocols (Stratagene) using a 2.0 kb BamHI-
gies at the junctions. In addition, sister chromatid fusion EcoRI fragment derived from the JH-specific FISH probe described
during BFB cycles appears to occur efficiently in the above as a probe. Single plaques were purified, subcloned, and
sequenced. In the case of lambda ZAPII clones, the inserts wereabsence of NHEJ, implying that other pathways play a
excised according to the protocol provided (Stratagene). Positivemajor role, with some evidence implicating the microho-
clones were verified by restriction analysis and hybridization. Se-mology-based pathway (e.g., the JH-JH fusion). In any quencing of subcloned inserts was performed by a core facility
case, this poorly understood end-joining pathway repre- using T7 or T3 primers. To obtain junctional sequences, an internal
sents an important area of future study in the context JH primer was required for some tumors: KMO123, 5-GGACTTTT
of genomic stability and tumorigenesis. We further note CAGGCTCCACCAGACC-3. As an alternative strategy, a circular
PCR protocol was used for cloning and sequencing the junction break-that complicons are associated with multiple stages of
points (Megonigal et al., 1998). Briefly, after EcoRI digestion, frag-tumor progression (Kuehl and Bergsagel, 2002; Schwab,
ments were circularized by dilution and overnight ligation. Ligation1999). For example, in breast cancer, complicon forma-
reactions were used directly as PCR templates. Appropriately sized
tion involving the c-erbB-2 gene has been implicated PCR products were subcloned into the TOPO cloning vector (In-
in progression from in situ lesions to overt carcinoma vitrogen), and screened using a JH probe (Gao et al., 2000). Colonies
(Coene et al., 1997). Most tumors are compromised for that positively hybridized with the JH probe were then purified, and
plasmid DNA was isolated and sequenced as described above.cell cycle checkpoints, often due to p53 deficiency.
Primers for circular PCR were CZO1, 5-GTTGAGGATTCAGCCGAMoreover, even haploinsufficiency for Lig4 in an Ink4a/
AACTGGAGAG-3 and CZO2, 5-CTTACCTGAGGAGACGGTGACTArf null background resulted in increased rates of solid
GAG-3.
tumors (Sharpless et al., 2001). Overall, our findings sug-
gest that complicon formation may be common in many Adoptive Transfer Experiments
checkpoint-deficient tumors secondary to deficient or Liver cells were collected from neonatal mice and stored on ice
while DNA samples were extracted and used for genotyping byinsufficient DSBR.
PCR. Lig4, p53 double mutant cells were transplanted into four
8- to 12-week-old RAG2-deficient male mice. Recipient mice were
Experimental Procedures irradiated with 200 rad before injection, and 2 million liver cells
were transferred to each recipient. Recipient mice were sacrificed
Generation of Complex Mouse Genotypes 8 weeks after injection when tumor masses were apparent. Tumor
Lig IV/ (Frank et al., 1998) or XRCC4/ mice (Gao et al., 1998) samples were collected and analyzed as described above.
were bred with p53-deficient mice (Donehower et al., 1992) to gener-
ate doubly deficient mice. XRCC4/, p53/ mice were also bred Acknowledgments
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